Health care workers across the U.S. are getting a new arrow in their quiver.
On Friday, just one week after Pfizer and BioNTech's COVID-19 vaccine received a federal green light, the Food and Drug Administration formally authorized a second vaccine for emergency use — this one developed by Moderna. The biotech upstart won authorization for use in adults following extensive federal analysis of the vaccine, which the FDA found to be 94% effective at preventing the disease.
"With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day," said a statement by FDA Commissioner Dr. Stephen M. Hahn.
The FDA decision represents another leap forward in the effort to combat the coronavirus, which has already killed more than 300,000 people in the U.S. alone. Since the Pfizer vaccine's authorization last week, health and defense officials have launched a vast effort to distribute millions of doses across the country. Health care workers and older adults were first in line for the inoculations when providers began administering them Monday.
In a push to inspire public confidence in the vaccine, Vice President Pence on Friday became the country's highest-ranking official so far to have it administered. Pence, his wife, Karen, and Surgeon General Jerome Adams all received their shots during a televised event at the White House.
Amid the flurry surrounding the Pfizer vaccine's rollout, Moderna's alternative was making steady headway in its own push toward authorization. The FDA released a glowing analysis of the vaccine on Tuesday, finding "no specific safety concerns." On Thursday, an outside panel of health care experts from across the U.S. unanimously recommended the vaccine with one abstention.
"The question that's being asked us is, 'Do we have enough evidence in hand to say that the benefits of this vaccine outweigh what at the moment, as far as severe safety issues go, are theoretical risks?' " Dr. Paul Offit, panel member and vaccine researcher at the Children's Hospital of Philadelphia, said during the hours-long recorded meeting.
"I think the answer to that question is clearly yes. I mean, the question is never 'When do you know everything?' It's 'When do you know enough?' "
Offit's point also gets at a crucial challenge faced by the federal regulators who have been tasked with evaluating these vaccines more quickly than they normally would. In an effort to expedite the process, the FDA — and other health regulators around the world — have loosened their usual approval procedures and adopted a more urgent mechanism known as emergency use authorization.
Moderna said it that it will deliver about 20 million doses by the end of December under its federal supply contract.
Now, attentions are turning to the Moderna vaccine's distribution. Like the Pfizer vaccine, the Moderna product uses messenger RNA technology — which, in the FDA's words, teaches the body's cells "how to make a protein — or even just a piece of a protein — that triggers an immune response inside our bodies."
"That immune response, which produces antibodies, is what protects us from getting infected if the real virus enters our bodies," the agency says.
Unlike the Pfizer vaccine, though, Moderna's product does not need to be stored at extremely low temperatures, potentially making it accessible for more communities. Balanced against that is the fact that the smaller biotech firm, in contrast with the pharmaceutical giant Pfizer, may face some steeper challenges meeting the extraordinary demand for inoculations.
But Dr. Anthony Fauci says he is hopeful that initial distribution will happen quickly.
"I would anticipate that we likely will see shots in the arm by the very early part of next week," the director of the National Institute of Allergy and Infectious Diseases told NBC's Today show Friday in advance of the FDA's authorization. "I would hope Monday or Tuesday."
Fauci's institute was instrumental in the development of the Moderna vaccine — from some of the basic science to bankrolling clinical testing. In August, the institute told NPR its contributions to the studies of the Moderna vaccine would cost taxpayers more than $400 million.
Operation Warp Speed, the crash federal project for vaccine development, poured in $955 million to support development of the Moderna vaccine, including the expanded phase 3 study that provided the data that made possible the emergency use authorization.